The Manufacturers Life Insurance Company Grows Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM

The Manufacturers Life Insurance Company lifted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 63.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 55,693 shares of the company's stock after purchasing an additional 21,579 shares during the period. The Manufacturers Life Insurance Company owned 0.09% of Mirum Pharmaceuticals worth $5,145,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in MIRM. Cullen Frost Bankers Inc. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $32,000. CIBC Private Wealth Group LLC acquired a new position in Mirum Pharmaceuticals during the fourth quarter worth $32,000. Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals in the 3rd quarter valued at $33,000. Finally, Comerica Bank grew its holdings in Mirum Pharmaceuticals by 45.1% in the 1st quarter. Comerica Bank now owns 895 shares of the company's stock valued at $40,000 after buying an additional 278 shares in the last quarter.

Key Stories Impacting Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum reported second-quarter revenue of approximately $176.2 million, ahead of the $166.3 million analyst consensus and up 37.9% year over year. Growth from Livmarli and other bile-acid medicines supported the performance. Mirum Q2 earnings and 2026 outlook
• Positive Sentiment: The company raised its 2026 revenue guidance to $680 million-$700 million, above the roughly $675.1 million consensus estimate, reinforcing expectations for continued product-driven growth.
• Positive Sentiment: Despite reducing their targets, TD Cowen and HC Wainwright maintained “buy” ratings at $140, while Citizens JMP kept a “market outperform” rating with a $137 target. These targets imply substantial potential upside from recent trading levels. Analyst price target updates
• Neutral Sentiment: Analysts continue to view Mirum favorably overall, but the target reductions—from as high as $185 previously—indicate that near-term risks and valuation assumptions have become more cautious.
• Negative Sentiment: Citizens warned that the FDA made an “unexpected” request for an additional Phase 3 study, clouding Mirum’s near-term outlook. The request raises potential development costs and could delay regulatory progress, which was the primary catalyst behind the selloff. Citizens FDA assessment
• Negative Sentiment: Second-quarter earnings missed expectations: Mirum reported a larger-than-expected per-share loss, while the loss widened from the prior-year period. The company remains unprofitable, increasing investor sensitivity to clinical spending and regulatory delays. Mirum quarterly earnings report
• Negative Sentiment: Senior Vice President Jolanda Howe sold 1,840 shares worth approximately $193,734 under a pre-arranged Rule 10b5-1 plan. The scheduled nature limits its significance, but the transaction reduced her direct holdings by about 59%. Mirum insider sale

Mirum Pharmaceuticals Stock Down 11.0%

Shares of NASDAQ:MIRM opened at $94.11 on Friday. The firm has a market capitalization of $5.74 billion, a PE ratio of -6.47 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 1 year low of $54.74 and a 1 year high of $130.00. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.09 and a quick ratio of 1.99. The firm's 50-day moving average is $110.35 and its two-hundred day moving average is $101.79.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 139.18% and a negative return on equity of 26.88%. The business had revenue of $176.24 million during the quarter, compared to analysts' expectations of $166.33 million. During the same period in the previous year, the business posted ($0.12) EPS. The company's revenue for the quarter was up 37.9% compared to the same quarter last year. Analysts predict that Mirum Pharmaceuticals, Inc. will post -2.01 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on MIRM shares. Wolfe Research started coverage on Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an "outperform" rating and a $145.00 price target on the stock. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. CLSA set a $146.00 price objective on shares of Mirum Pharmaceuticals in a research report on Monday, June 15th. Robert W. Baird set a $123.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday. Finally, Evercore reiterated an "outperform" rating and issued a $138.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $137.33.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 5,000 shares of the business's stock in a transaction on Monday, July 6th. The shares were sold at an average price of $122.25, for a total value of $611,250.00. Following the completion of the transaction, the chief financial officer owned 42,181 shares in the company, valued at $5,156,627.25. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 30,000 shares of the company's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $95.84, for a total value of $2,875,200.00. Following the sale, the chief executive officer directly owned 194,309 shares in the company, valued at $18,622,574.56. This represents a 13.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 67,155 shares of company stock valued at $7,185,662 in the last 90 days. Company insiders own 8.32% of the company's stock.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company's primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum's lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.

Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source